Literature DB >> 17597328

A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP.

Christel Depienne, Estelle Fedirko, Jean-Marc Faucheux, Sylvie Forlani, Bernard Bricka, Cyril Goizet, Sylvie Lesourd, Giovanni Stevanin, Merle Ruberg, Alexandra Durr, Alexis Brice.   

Abstract

SPG4/SPAST, the gene-encoding spastin, is responsible for the most frequent form of autosomal dominant hereditary spastic paraplegia (HSP). SPG4-HSP is a heterogeneous disorder characterized by both interfamilial and intrafamilial variation, especially regarding the severity and the age at onset. In this study, we investigated the origin of the mutation and the factors involved in intra-familial heterogeneity in a family with a SPG4 mutation. We demonstrated that the mutation occurred de novo and show evidence of somatic mosaicism in the grandfather, who was the only affected member of six siblings. His disease began at age 55, much later than in his daughter, who had onset at age 18, and his grandson, in whom onset was at age 5. These observations indicate that de novo mutations can occur in SPG4, and that somatic mosaicism might account for intra-familial variation in SPG4-linked HSP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597328     DOI: 10.1007/s10048-007-0090-4

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  5 in total

1.  A novel assay for allelic discrimination that combines the fluorogenic 5' nuclease polymerase chain reaction (TaqMan) and mismatch amplification mutation assay.

Authors:  W E Glaab; T R Skopek
Journal:  Mutat Res       Date:  1999-11-29       Impact factor: 2.433

Review 2.  Hereditary spastic paraplegia: spastin phenotype and function.

Authors:  John K Fink; Shirley Rainier
Journal:  Arch Neurol       Date:  2004-06

3.  Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia.

Authors:  I K Svenson; A E Ashley-Koch; P C Gaskell; T J Riney; W J Cumming; H M Kingston; E L Hogan; R M Boustany; J M Vance; M A Nance; M A Pericak-Vance; D A Marchuk
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

4.  Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.

Authors:  C Depienne; C Tallaksen; J Y Lephay; B Bricka; S Poea-Guyon; B Fontaine; P Labauge; A Brice; A Durr
Journal:  J Med Genet       Date:  2005-07-31       Impact factor: 6.318

5.  Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia.

Authors:  N Fonknechten; D Mavel; P Byrne; C S Davoine; C Cruaud; D Bönsch; D Boentsch; D Samson; P Coutinho; M Hutchinson; P McMonagle; J M Burgunder; A Tartaglione; O Heinzlef; I Feki; T Deufel; N Parfrey; A Brice; B Fontaine; J F Prud'homme; J Weissenbach; A Dürr; J Hazan
Journal:  Hum Mol Genet       Date:  2000-03-01       Impact factor: 6.150

  5 in total
  12 in total

Review 1.  Recent advances in the genetics of spastic paraplegias.

Authors:  Giovanni Stevanin; Merle Ruberg; Alexis Brice
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

2.  Thalamic atrophy in patients with pure hereditary spastic paraplegia type 4.

Authors:  Francisco Grandas; Manuel Desco; Francisco J Navas-Sánchez; Alberto Fernández-Pena; Daniel Martín de Blas; Yasser Alemán-Gómez; Luís Marcos-Vidal; Juan A Guzmán-de-Villoria; Pilar Fernández-García; Julia Romero; Irene Catalina; Laura Lillo; José L Muñoz-Blanco; Andrés Ordoñez-Ugalde; Beatriz Quintáns; Julio Pardo; María-Jesús Sobrido; Susanna Carmona
Journal:  J Neurol       Date:  2021-01-28       Impact factor: 4.849

3.  ZFYVE26/SPASTIZIN and SPG11/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis.

Authors:  Chiara Vantaggiato; Elena Panzeri; Marianna Castelli; Andrea Citterio; Alessia Arnoldi; Filippo Maria Santorelli; Rocco Liguori; Marina Scarlato; Olimpia Musumeci; Antonio Toscano; Emilio Clementi; Maria Teresa Bassi
Journal:  Autophagy       Date:  2018-09-13       Impact factor: 16.016

4.  Evidence of mosaicism in SPAST variant carriers in four French families.

Authors:  Chloé Angelini; Cyril Goizet; Samia Ait Said; William Camu; Christel Depienne; Bénédicte Heron; Bophara Kol; Marine Guillaud-Bataille; Perrine Pennamen; Caroline Rooryck; Clarisse Scherer-Gagou; Laurène Tissier; Giovanni Stevanin; Eric Leguern; Guillaume Banneau
Journal:  Eur J Hum Genet       Date:  2021-05-06       Impact factor: 5.351

Review 5.  Inflammation in Parkinson's disease: role of glucocorticoids.

Authors:  María-Trinidad Herrero; Cristina Estrada; Layal Maatouk; Sheela Vyas
Journal:  Front Neuroanat       Date:  2015-04-02       Impact factor: 3.856

Review 6.  Hypothesis: somatic mosaicism and Parkinson disease.

Authors:  Han-Joon Kim; Beom S Jeon
Journal:  Exp Neurobiol       Date:  2014-12-12       Impact factor: 3.261

Review 7.  The role of de novo mutations in adult-onset neurodegenerative disorders.

Authors:  Gaël Nicolas; Joris A Veltman
Journal:  Acta Neuropathol       Date:  2018-11-26       Impact factor: 17.088

8.  Defective autophagy in spastizin mutated patients with hereditary spastic paraparesis type 15.

Authors:  Chiara Vantaggiato; Claudia Crimella; Giovanni Airoldi; Roman Polishchuk; Sara Bonato; Erika Brighina; Marina Scarlato; Olimpia Musumeci; Antonio Toscano; Andrea Martinuzzi; Filippo Maria Santorelli; Andrea Ballabio; Nereo Bresolin; Emilio Clementi; Maria Teresa Bassi
Journal:  Brain       Date:  2013-09-11       Impact factor: 13.501

9.  Diagnosis, investigation and management of hereditary spastic paraplegias in the era of next-generation sequencing.

Authors:  Anke Hensiek; Stephen Kirker; Evan Reid
Journal:  J Neurol       Date:  2014-12-06       Impact factor: 4.849

10.  Somatic alpha-synuclein mutations in Parkinson's disease: hypothesis and preliminary data.

Authors:  Christos Proukakis; Henry Houlden; Anthony H Schapira
Journal:  Mov Disord       Date:  2013-05-14       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.